Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer
The purpose of this study is to test the safety of durvalumab (MEDI4736) and tremelimumab in combination with radiation therapy and find out what effects, if any, this combination has on people, and whether it improves overall survival.
Metastatic Anaplastic Thyroid Cancer
DRUG: durvalumab|DRUG: tremelimumab|RADIATION: Stereotactic Body Radiotherapy (SBRT)
overall survival, RECIST 1.1, 1 year
The purpose of this study is to test the safety of durvalumab (MEDI4736) and tremelimumab in combination with radiation therapy and find out what effects, if any, this combination has on people, and whether it improves overall survival.